SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published article

18 Oct 2013 07:00

RNS Number : 8024Q
Tristel PLC
18 October 2013
 



Tristel plc

("Tristel" or "the Company")

 

Peer-reviewed published article supporting Tristel's technology and products

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of an article in a peer-reviewed journal that describes the benefits of Tristel products.

 

The study is titled "A randomised single-blind comparison of the effectiveness of the high-level disinfectants Tristel Fuse (chlorine dioxide) and Cidex OPA (ortho-phthaldehyde) for use with flexible cystoscopes". It has been published in The British Journal of Urology International (on line 10.1111 BJU 12208) and will be published within the Urological Society of Australia and New Zealand (special issue volume 112).

 

The article compares the effectiveness, safety and cost of Tristel's chlorine dioxide Fuse chemistry with Cidex OPA (Johnson & Johnson, USA), in an automated endoscope reprocessor (Medivators Inc, USA) for high level disinfection of flexible cystoscopes.

 

Tristel Fuse, which was used within the Company's Stella decontamination system, was found to be as effective, more economic and easier for the nursing staff to use than the American products with which it was compared.

 

Tristel CEO, Paul Swinney, commented: "This study was initiated in 2009 by the Department of Urology, Tauranga Hospital, New Zealand, and the initial results were reported at the Societe Internationale d'Urologie congress, Shanghai, 2011.

 

"This is the first published study that compares our Tristel Fuse and Stella system with one of the world's leading combinations of disinfectant and endoscope washing machine. It demonstrates that our chlorine dioxide technology is just as safe and effective as the world's most widely used medical instrument disinfectant, whilst producing cost savings for hospitals.

 

"This study joins the growing body of published scientific evidence demonstrating that Tristel products are superior to the incumbent technologies still being used around the world."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRANKODPPBDDDKD
Date   Source Headline
27th Mar 20188:19 amRNSIssue of Equity
26th Mar 20187:00 amRNSCommercial collaboration with Parker Laboratories
8th Mar 201810:58 amRNSIssue of Equity
20th Feb 20187:00 amRNSHalf-year Report
8th Feb 20182:19 pmRNSHolding(s) in Company
26th Jan 20187:00 amRNSIssue of Equity
24th Jan 20187:00 amRNSStudy shows comparable efficacy of Tristel Wipes
17th Jan 20187:00 amRNSInvestor results presentation
12th Dec 20172:57 pmRNSResult of AGM
12th Dec 20177:00 amRNSAGM Statement & notice of results
27th Nov 201710:35 amRNSIssue of Equity
23rd Nov 20173:24 pmRNSClarification of AGM timing
14th Nov 201710:34 amRNSIssue of Equity
2nd Nov 20177:00 amRNSDirectors dealing/grant of options
23rd Oct 20174:41 pmRNSIssue of Equity
19th Oct 20177:01 amRNSDirector Appointment
19th Oct 20177:00 amRNSFinal Results
3rd Oct 20177:00 amRNSTiming of EPA approval
19th Sep 20177:00 amRNSInvestor results presentation
18th Sep 20171:44 pmRNSIssue of Equity
22nd Aug 201712:08 pmRNSIssue of Equity
18th Aug 20171:31 pmRNSDirector/PDMR Dealing - replacement
17th Aug 20177:00 amRNSDirector/PDMR Dealing
7th Aug 20172:29 pmRNSIssue of Equity
24th Jul 20179:46 amRNSIssue of Equity
19th Jul 20177:00 amRNSTrading update & Notice of results
5th Jul 20177:00 amRNSIssue of Equity
3rd Jul 20171:59 pmRNSStrategic investment
3rd Jul 20177:00 amRNSSubmission to EPA & subsidiary incorporated in USA
13th Jun 20177:00 amRNSIssue of Equity
24th May 20177:00 amRNSShareholder Open Day & Notice of Trading Update
19th May 20173:34 pmRNSIssue of Equity
3rd May 20178:27 amRNSIssue of Equity
7th Apr 20175:04 pmRNSResult of Placing
7th Apr 20172:07 pmRNSProposed Secondary Placing
28th Mar 20172:38 pmRNSIssue of Equity
7th Mar 20179:41 amRNSIssue of Equity
6th Mar 20177:00 amRNSIssue of Equity
27th Feb 20177:00 amRNSProducts approved by Australia's TGA
27th Feb 20177:00 amRNSJournal of Ultrasound in Medicine & Biology
23rd Feb 20177:00 amRNSHalf-year Report
25th Jan 20177:00 amRNSInvestor results presentation
24th Jan 20177:00 amRNSJournal of Infection Prevention: TSTL wipes study
17th Jan 201712:31 pmRNSDirector / PDMR Shareholding
13th Dec 201612:30 pmRNSResult of AGM
13th Dec 20167:00 amRNSAGM Statement
6th Dec 20167:00 amRNSIssue of Equity
28th Nov 20163:42 pmRNSNotice of AGM correction
23rd Nov 201612:37 pmRNSIssue of Equity
17th Oct 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.